Prevail Therapeutics to Present at Upcoming Investor Conferences
September 02, 2020 17:18 ET
|
Prevail Therapeutics
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results
August 05, 2020 16:01 ET
|
Prevail Therapeutics
NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR006
July 27, 2020 16:05 ET
|
Prevail Therapeutics
NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative Diseases at the Virtual 2020 Alzheimer’s Association International Conference
July 22, 2020 17:01 ET
|
Prevail Therapeutics
Preclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases Company Provides Overview of Planned Phase 1/2 PR006...
Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel
June 04, 2020 07:00 ET
|
Prevail Therapeutics
NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics to Present at The Jefferies Virtual Global Healthcare Conference
May 26, 2020 16:01 ET
|
Prevail Therapeutics
NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
Prevail Therapeutics to Participate in Fireside Chat at Chardan 4th Annual Genetic Medicines Manufacturing Summit
May 21, 2020 17:46 ET
|
Prevail Therapeutics
CEO, CTO to Discuss Company’s Manufacturing and CMC Strategy and Overall Industry Trends NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company...